Ø. Bruserud

Ø. Bruserud, H. Reikvam, Clara-Cecilie Günther, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?

Ø. Bruserud, E. Ersvær, G. Melve, 2011, Cancer Immunology, Immunotherapy.

Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) – gene transcription, cell cycle regulation, metabolism and intercellular communication

Ø. Bruserud, A. Brenner, H. Reikvam, 2015, Expert review of hematology.

Heat shock protein 70 – the next chaperone to target in the treatment of human acute myelogenous leukemia?

Ø. Bruserud, A. Brenner, H. Reikvam, 2014, Expert opinion on therapeutic targets.

Acute myelogenous leukemia in a patient with Li–Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report

A. Børresen-Dale, Ø. Bruserud, B. Gjertsen, 2006, Leukemia.

Cellular immune responses in multiple myeloma patients with treatment-induced cytopenia early after high-dose chemotherapy and autologous peripheral blood stem cell transplantation.

Ø. Bruserud, I. Nesthus, M. Sjo, 2004, Leukemia research.

Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia

Ø. Bruserud, T. Tvedt, H. Reikvam, 2018, Expert opinion on investigational drugs.

Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia

Ø. Bruserud, A. Brenner, Håkon Reikvam, 2022, Molecules.

How should clinical data be included in experimental studies of cancer immunology?

Ø. Bruserud, B. Gjertsen, 2004, Cancer Immunology, Immunotherapy.

A critical review of T cell targeting immunotherapy in pancreatic cancer: only a hypothesis or a real hope for the patients?

Ø. Bruserud, N. Glenjen, 2002, Expert opinion on biological therapy.

Targeting of polo-like kinases and their cross talk with Aurora kinases – possible therapeutic strategies in human acute myeloid leukemia?

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2012, Expert opinion on investigational drugs.

LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitro

Ø. Bruserud, J. Lillehaug, S. Døskeland, 2007, Molecular Cancer.

Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer—What Can We Learn from the Hematological Experience?

H. H. Aarstad, Ø. Bruserud, T. Tvedt, 2020, Cancers.

The proteasome inhibitors bortezomib and PR‐171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

Ø. Bruserud, B. Gjertsen, J. Lorens, 2007, British journal of haematology.

Hematopoiesis, Inflammation and Aging—The Biological Background and Clinical Impact of Anemia and Increased C-Reactive Protein Levels on Elderly Individuals

Ø. Bruserud, Anh Khoi Vo, Håkon Rekvam, 2022, Journal of clinical medicine.

Insulin-like Growth Factor-1 (IGF-1) is a Costimulator of the Expansion of Lineage Committed Cells Derived from Peripheral Blood Mobilized CD34(+) Cells in Multiple Myeloma Patients.

T. Hervig, Ø. Bruserud, J. Olweus, 1999, Hematology.

Myeloproliferative neoplasms and JAK2 mutations.

Ø. Bruserud, H. Reikvam, A. Aarsand, 2016, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Cytokine profiling and post‐transfusion haemoglobin increment in patients with haematological diseases

T. Hervig, Ø. Bruserud, H. Reikvam, 2018, Vox sanguinis.

The Acute Phase Reaction and Its Prognostic Impact in Patients with Head and Neck Squamous Cell Carcinoma: Single Biomarkers Including C-Reactive Protein Versus Biomarker Profiles

Svein Erik Emblem Moe, H. H. Aarstad, H. Aarstad, 2020, Biomedicines.

p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy

Sigrun M. Hjelle, Ø. Bruserud, B. Gjertsen, 2021, Cells.

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2018, Case reports in hematology.

High-dose etoposide in allogeneic stem cell transplantation

Ø. Bruserud, T. Tvedt, H. Reikvam, 2012, Cancer Chemotherapy and Pharmacology.

Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia

T. H. Bø, I. Jonassen, Ø. Bruserud, 2009, BMC Cancer.

Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cell.

Ø. Bruserud, B. Gjertsen, A. Ryningen, 2007, Current pharmaceutical biotechnology.

Histone Deacetylase Inhibitors in Cancer Treatment: A Review of the Clinical Toxicity and the Modulation of Gene Expression in Cancer Cells

Ø. Bruserud, B. Gjertsen, E. Ersvær, 2007 .

Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release

Ø. Bruserud, H. Reikvam, E. Ersvær, 2010, Expert opinion on investigational drugs.

Bronchiolitis obliterans syndrome in adults after allogeneic stem cell transplantation-pathophysiology, diagnostics and treatment

Ø. Bruserud, H. Reikvam, I. Grønningsæter, 2017, Expert review of clinical immunology.

CDC25 Inhibition in Acute Myeloid Leukemia–A Study of Patient Heterogeneity and the Effects of Different Inhibitors

Ø. Bruserud, A. Lavecchia, A. Brenner, 2017, Molecules.

Soluble mediators released by acute myeloid leukemia cells increase capillary‐like networks

Ø. Bruserud, J. Lorens, H. Reikvam, 2012, European journal of haematology.

In vitro effects of native human acute myelogenous leukemia blasts on fibroblasts and osteoblasts

Ø. Bruserud, E. Ersvær, A. Ryningen, 2004, International journal of cancer.

Interleukin 4 responses in acute leukaemia patients with severe chemotherapy‐induced leucopenia

Ø. Bruserud, A. Halstensen, E. Ulvestad, 1997, European journal of haematology.

Endocan in Acute Leukemia: Current Knowledge and Future Perspectives

Ø. Bruserud, K. Hatfield, P. Lassalle, 2022, Biomolecules.

The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile

H. H. Aarstad, L. Bostad, K. Hjelle, 2020, Cancers.

Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease.

Ø. Bruserud, E. Ersvaer, M. Sjo, 2010, European cytokine network.

Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome

Ø. Bruserud, S. Døskeland, F. Selheim, 2018, International journal of molecular sciences.

Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90.

Ø. Bruserud, K. Kalland, B. Gjertsen, 2006, Leukemia research.

Flow cytometric measurement of apoptosis and necrosis in cryopreserved PBPC concentrates from patients with malignant diseases

Ø. Bruserud, B. Gjertsen, J. Abrahamsen, 2002, Bone Marrow Transplantation.

Immunological Heterogeneity of Healthy Peripheral Blood Stem Cell Donors—Effects of Granulocyte Colony-Stimulating Factor on Inflammatory Responses

Ø. Bruserud, T. Tvedt, A. Brenner, 2018, International journal of molecular sciences.

The constitutive protease release by primary human acute myeloid leukemia cells

Ø. Bruserud, A. Brenner, Maria Honnemyr, 2017, Journal of Cancer Research and Clinical Oncology.

Autologous Stem Cell Transplantation in the Treatment of Amyloidosis – Can Manipulation of the Autograft Reduce Treatment-Related Toxicity?

Ø. Bruserud, Ç. A. Akkök, 2011 .

Expression patterns of chemokine receptors on circulating T cells from myelodysplastic syndrome patients

Ø. Bruserud, A. Kittang, B. Mannsăker, 2013, Oncoimmunology.

Extracorporeal photopheresis (photochemotherapy) in the treatment of acute and chronic graft versus host disease: immunological mechanisms and the results from clinical studies

Ø. Bruserud, T. Tvedt, H. Reikvam, 2014, Cancer Immunology, Immunotherapy.

A Pilot Study of Circulating Monocyte Subsets in Patients Treated with Stem Cell Transplantation for High-Risk Hematological Malignancies

Ø. Bruserud, E. Ersvær, A. Ryningen, 2020, Medicina.

Combination of Intensive Chemotherapy and Anticancer Vaccines in the Treatment of Human Malignancies: The Hematological Experience

T. Hervig, Ø. Bruserud, E. Ersvær, 2010, Journal of biomedicine & biotechnology.

Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis

Ø. Bruserud, H. Reikvam, R. Lindås, 2014, SpringerPlus.

Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome

Ø. Bruserud, G. Mufti, T. Seidl, 2015, Oncoimmunology.

Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia‐associated antigen associated with autoantibody response in a subset of patients

Ø. Bruserud, B. Gjertsen, Jian-ying Zhang, 2007, European journal of haematology.

Long‐term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells

Ø. Bruserud, E. Ersvær, A. Ryningen, 2009, Transfusion.

Immunotherapy in chronic lymphocytic leukemia

Ø. Bruserud, B. Gjertsen, E. McCormack, 2006, Cancer Immunology, Immunotherapy.

Serum levels of angiogenin, basic fibroblast growth factor and endostatin in patients receiving intensive chemotherapy for acute myelogenous leukemia

Ø. Bruserud, K. A. Mosevoll, N. Glenjen, 2002, International journal of cancer.

Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts: studies of allostimulated interferon-γ secretion

Ø. Bruserud, S. Berentsen, I. Nesthus, 1997, Cancer Immunology, Immunotherapy.

Thrombotic complications in adult patients with severe single coagulation factor or platelet defects – an overview

Ø. Bruserud, Hanne Skaadel, 2019, Expert review of hematology.

Therapeutic targeting of NF-κB in myelodysplastic syndromes and acute myeloid leukaemia – the biological heterogeneity

Ø. Bruserud, H. Reikvam, 2010, Expert opinion on therapeutic targets.

Insulin‐Like Growth Factor‐1 (IGF‐1) has a Costimulatory Effect on Proliferation of Committed Progenitors Derived from Human Umbilical Cord CD34+ Cells

Ø. Bruserud, J. Olweus, R. Bjerknes, 1998, Stem cells.

The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes

Ø. Bruserud, A. Brenner, A. Kittang, 2016, International journal of molecular sciences.

Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis.

Ø. Bruserud, T. Tvedt, H. Reikvam, 2015, Thrombosis research.

Circadian variations do not have a major impact on serum levels of soluble (s) L-selectin (CD63L), s-intercellular adhesion molecule 1 (sICAM-1/CD54) and thrombopoietin in healthy individuals

Ø. Bruserud, K. A. Mosevold, 2002, Scandinavian journal of clinical and laboratory investigation.

Serum levels of angioregulatory mediators in healthy individuals depend on age and physical activity: Studies of angiogenin, basic fibroblast growth factor, leptin and endostatin

Ø. Bruserud, R. Lindås, F. Grøvan, 2005, Scandinavian journal of clinical and laboratory investigation.

Secretion of IL‐2, IL‐3, IL‐4, IL‐6 and GM‐CSF by CD4+ and CD8+ TCRαβ+ T‐Cell Clones derived early after Allogeneic Bone Marrow Transplantation

Ø. Bruserud, G. Ehninger, W. Hamann, 1993 .

Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?

Ø. Bruserud, B. Gjertsen, K. Tronstad, 2006, Cancer Immunology, Immunotherapy.

Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma.

T. Hervig, Ø. Bruserud, H. Reikvam, 2013, Cytotherapy.

The Progression of Acute Myeloid Leukemia from First Diagnosis to Chemoresistant Relapse: A Comparison of Proteomic and Phosphoproteomic Profiles

Ø. Bruserud, S. Døskeland, R. Hovland, 2020, Cancers.

Effects of cytarabine on activation of human T cells – cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid

Ø. Bruserud, A. Brenner, H. Reikvam, 2015, BMC Pharmacology and Toxicology.

Necrotizing Bacterial Myositis as the Initial Presentation of Severe Aplastic Anaemia

Ø. Bruserud, T. Tvedt, L. Helgeland, 2021, Case reports in hematology.

NecrotizingBacterialMyositis as the Initial Presentation of Severe Aplastic Anaemia

Ø. Bruserud, T. Tvedt, K. Larsen, 2021 .

The Role of Human Class II Molecules in Activation of T4 Lymphocytes

E. Thorsby, Ø. Bruserud, E. Qvigstad, 1986 .

Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia

T. Hervig, Ø. Bruserud, H. Reikvam, 2013, Transfusion medicine.

The Cellular Immune System of Patients with Acute Leukemia and Severe Chemotherapy-Induced Leukopenia: Characterization of T Lymphocyte Subsets Responsive to IL-16 and IL-17

Ø. Bruserud, E. Ulvestad, H. L. von Volkman, 2001, Acta Haematologica.

Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators

Ø. Bruserud, K. Kalland, B. Gjertsen, 2009, British journal of haematology.

How should quality of life assessment be integrated in the evaluation of patients with acute myeloid leukemia?

Ø. Bruserud, T. Tvedt, H. Reikvam, 2016 .

Use of marine toxins in combination with cytotoxic drugs for induction of apoptosis in acute myelogenous leukaemia cells

Ø. Bruserud, S. Døskeland, B. Gjertsen, 2002, Expert opinion on biological therapy.

Characterization of Clonogenic Progenitors in Autologous Peripheral Blood Stem Cell Grafts: Evaluation of a Simple In Vitro Assay Suitable for Routine Clinical Use

Ø. Bruserud, P. Ernst, A. Bakken, 2003, Hematology.

Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia

Katarina M. Jørgensen, I. Jonassen, Ø. Bruserud, 2011, Blood cancer journal.

Treatment with valproic acid, all-trans retinoic acid (ATRA) and theophyllamine for 9 days caused a persistent increase in peripheral blood platelet counts for a patient with acute myelogenous leukemia

Ø. Bruserud, A. Ryningen, C. Stapnes, 2006, Acta oncologica.

Rethinking the role of osteopontin in human acute myeloid leukemia

Ø. Bruserud, A. Brenner, F. Berven, 2017, Leukemia & lymphoma.

Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML)

Ø. Bruserud, B. Gjertsen, M. Omsland, 2016, Oncotarget.

Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2013, Expert opinion on investigational drugs.

Inhibition of Mammalian Target of Rapamycin in Human Acute Myeloid Leukemia Cells Has Diverse Effects That Depend on the Environmental In Vitro Stress

Ø. Bruserud, H. Reikvam, A. Ryningen, 2012, Bone marrow research.

Functional differentiation of acute myeloid leukaemia blast cells

Ø. Bruserud, A. Halstensen, C. Bassøe, 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

The Effect of Disodium Cromoglycate on In Vitro Proliferation of Peripheral Blood Mononuclear Cells from Allergic and Healthy Donors

Ø. Bruserud, S. Elsayed, E. Holen, 1992, Scandinavian journal of immunology.

Pure Red Cell Aplasia with Del(20q) Sensitive for Immunosuppressive Treatment

Ø. Bruserud, H. Reikvam, R. Hovland, 2020, Case reports in hematology.

Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors

Ø. Bruserud, G. Melve, K. Hatfield, 2016, Metabolomics.

The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation

Ø. Bruserud, H. Reikvam, K. Hatfield, 2015, Metabolomics.

Metabolic Serum Profiles for Patients Receiving Allogeneic Stem Cell Transplantation: The Pretransplant Profile Differs for Patients with and without Posttransplant Capillary Leak Syndrome

Ø. Bruserud, H. Reikvam, K. Hatfield, 2015, Disease markers.

In vivo biological effects of ATRA in the treatment of AML

Ø. Bruserud, B. Gjertsen, A. Ryningen, 2008 .

The Role of the CD8‐Positive Subset of T Cells in Proliferative Responses to Soluble Antigens

E. Thorsby, Ø. Bruserud, L. Sollid, 1986, Scandinavian journal of immunology.

Mesenchymal Stem Cells Support Survival and Proliferation of Primary Human Acute Myeloid Leukemia Cells through Heterogeneous Molecular Mechanisms

Ø. Bruserud, A. Brenner, I. Nepstad, 2017, Front. Immunol..

Disease‐stabilizing treatment with all‐trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti‐leukemic treatment

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2012, American journal of hematology.

CD4+ TCRαβ+ T-cell clones derived shortly after allogeneic bone marrow transplantation: Theophyllamine and verapamil inhibit proliferation of functionally heterogeneous T-cells

Ø. Bruserud, G. Pawelec, Sarita Patel, 1992 .

Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia

Ø. Bruserud, M. Hernandez-Valladares, Elise Aasebø, 2018, Expert review of hematology.

Correction: Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells

Ø. Bruserud, H. Reikvam, K. Hatfield, 2017, Oncotarget.

Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells

Ø. Bruserud, H. Reikvam, K. Hatfield, 2013 .

Flt 3-mediated signaling in human acute myelogenous leukemia ( AML ) blasts : a functional characterization of the effects of Flt 3-ligand in AML cell populations with and without genetic Flt 3 abnormalities

Ø. Bruserud, B. Gjertsen, R. Hovland, 2003 .

IL-6 Responsiveness of CD4+ and CD8+ T Cells after Allogeneic Stem Cell Transplantation Differs between Patients and Is Associated with Previous Acute Graft versus Host Disease and Pretransplant Antithymocyte Globulin Therapy

Ø. Bruserud, T. Tvedt, S. Rose-John, 2022, Journal of clinical medicine.

A 35-year-old woman with influenza A-associated thrombotic thrombocytopenic purpura.

Ø. Bruserud, D. Hammenfors, A. Kittang, 2015, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Animal Survival Efficiently Kill Glioblastoma and Prolong Have a Functional Activation Advantage to Nk Cells with Kir2ds2 Immunogenotype

Ø. Bruserud, J. Zimmer, L. Leiss, 2022 .

THE SYSTEMIC METABOLIC PROFILE EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: EFFECTS OF ADEQUATE ENERGY SUPPORT ADMINISTERED THROUGH ENTERAL FEEDING TUBE.

Ø. Bruserud, T. Tvedt, P. Iversen, 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

In vitro culture of human osteosarcoma cell lines: a comparison of functional characteristics for cell lines cultured in medium without and with fetal calf serum

Ø. Bruserud, K. Tronstad, R. Berge, 2005, Journal of Cancer Research and Clinical Oncology.

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation

Ø. Bruserud, K. Kalland, H. Reikvam, 2010, European journal of haematology.

Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors

Ø. Bruserud, E. Ersvær, A. Ryningen, 2008, Hematology.

In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22.

Ø. Bruserud, A. Ryningen, A. Olsnes, 2008, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Lentinan: Hematopoietic, Immunological, and Efficacy Studies in a Syngeneic Model of Acute Myeloid Leukemia

Ø. Bruserud, B. Gjertsen, J. Skavland, 2010, Nutrition and cancer.

Effect of Verapamil on T‐Lymphocyte Activation in Vitro

Ø. Bruserud, 1985, Scandinavian journal of immunology.

Platelet‐derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts

Ø. Bruserud, E. Ulvestad, B. Foss, 2001, European journal of haematology.

Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels

Ø. Bruserud, K. Hatfield, N. Glenjen, 2005, European journal of haematology.

Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of normal polyclonal T cells and T lymphocyte clones derived early after allogeneic bone marrow transplantation

Ø. Bruserud, G. Pawelec, 1996, Cancer Immunology, Immunotherapy.

In vitro effects of R-verapamil on the cytokine environment and T-lymphocyte proliferation when human T-lymphocyte activation takes place in the presence of acute myelogenous leukemia blasts

Ø. Bruserud, 1996, Cancer Chemotherapy and Pharmacology.

Interleukin-13 secretion by normal and posttransplant T lymphocytes; in vitro studies of cellular immune responses in the presence of acute leukaemia blast cells

Ø. Bruserud, G. Pawelec, 1997, Cancer Immunology, Immunotherapy.

New Strategies in the Treatment of Acute Myelogenous Leukemia (AML): In Vitro Culture of AML Cells—The Present Use in Experimental Studies and the Possible Importance for Future Therapeutic Approaches

Ø. Bruserud, B. Gjertsen, Tien‐sheng Huang, 2001, Stem cells.

Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities.

Ø. Bruserud, B. Gjertsen, R. Hovland, 2003, Haematologica.

Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells

Ø. Bruserud, H. Reikvam, K. Hatfield, 2013, Oncotarget.

HLA-DR3 and -DR4 control T-lymphocyte responses to mumps and Coxsackie B4 virus: studies on patients with Type 1 (insulin-dependent) diabetes and healthy subjects

E. Thorsby, Ø. Bruserud, J. Jervell, 1985, Diabetologia.

The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis.

T. Hervig, Ø. Bruserud, H. Reikvam, 2018, Cytotherapy.

Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients

Ø. Bruserud, K. Hatfield, H. Reikvam, 2022, Cancers.

Genomic HLA‐DQβ Polymorphism Associated with Insulin‐Dependent Diabetes Mellitus

E. Thorsby, Ø. Bruserud, K. Lundin, 1987 .

IFN‐γ and TNF‐α secretion by CD4+ and CD8+ TCRαβ+ T‐cell clones derived early after allogeneic bone marrow transplantation

Ø. Bruserud, G. Pawelec, G. Ehninger, 1993 .

Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels

Ø. Bruserud, E. Ulvestad, 2000, Cancer Immunology, Immunotherapy.

Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes

Ø. Bruserud, J. Theorell, Y. Bryceson, 2016, Cancer Immunology, Immunotherapy.

Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells

Ø. Bruserud, E. Ulvestad, 2003, Cancer Immunology, Immunotherapy.

Is there a scientific basis for a recommended standardization of collection and cryopreservation of peripheral blood stem cell grafts?

T. Hervig, Ø. Bruserud, G. Melve, 2011, Cytotherapy.

Proteomics in acute myelogenous leukaemia (AML): methodological strategies and identification of protein targets for novel antileukaemic therapy.

Ø. Bruserud, B. Gjertsen, G. Sjøholt, 2005, Current drug targets.

In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma‐irradiated single‐donor platelet concentrates during long‐term storage

T. Hervig, Ø. Bruserud, T. Wentzel‐Larsen, 2007, Transfusion.

PLATELET SECRETION IN PBPC AUTOGRAFTS

Ø. Bruserud, B. Foss, J. Abrahamsen, 2002 .

Peripheral blood progenitor cell grafts contain high levels of platelet‐secreted mediators

Ø. Bruserud, B. Foss, J. Abrahamsen, 2001, Transfusion.

Myeloid Sarcoma after Allogenic Stem Cell Transplantation for Acute Myeloid Leukemia: Successful Consolidation Treatment Approaches in Two Patients

Ø. Bruserud, H. Reikvam, Aymen Ahmed, 2018, Case reports in oncological medicine.

Interleukin-6 in Allogeneic Stem Cell Transplantation: Its Possible Importance for Immunoregulation and As a Therapeutic Target

Ø. Bruserud, T. Tvedt, E. Ersvaer, 2017, Front. Immunol..

Targeted therapy in acute myeloid leukaemia: current status and future directions

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2009, Expert opinion on investigational drugs.

Animal models of acute myelogenous leukaemia – development, application and future perspectives

Ø. Bruserud, B. Gjertsen, B. Gjertsen, 2005, Leukemia.

Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators.

T. Hervig, Ø. Bruserud, A. Ryningen, 2009, Cytotherapy.

Effects of the Autophagy-Inhibiting Agent Chloroquine on Acute Myeloid Leukemia Cells; Characterization of Patient Heterogeneity

Ø. Bruserud, T. Tvedt, H. Reikvam, 2021, Journal of personalized medicine.

Iodinin (1,6-Dihydroxyphenazine 5,10-Dioxide) from Streptosporangium sp. Induces Apoptosis Selectively in Myeloid Leukemia Cell Lines and Patient Cells

Ø. Bruserud, S. Døskeland, H. Sletta, 2013, Marine drugs.

HLA Control of the Proliferative T Lymphocyte Response to Antigenic Determinants on Mumps Virus

E. Thorsby, Ø. Bruserud, 1985, Scandinavian journal of immunology.

A Subset of Patients with Acute Myeloid Leukemia Has Leukemia Cells Characterized by Chemokine Responsiveness and Altered Expression of Transcriptional as well as Angiogenic Regulators

Ø. Bruserud, A. Brenner, H. Reikvam, 2016, Front. Immunol..

The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia.

Ø. Bruserud, H. Reikvam, K. Hatfield, 2010, Current medicinal chemistry.

Lipoteichoic acid derived from Enterococcus faecalis modulates the functional characteristics of both normal peripheral blood leukocytes and native human acute myelogenous leukemia blasts

Ø. Bruserud, Ø. Wendelbo, K. Paulsen, 2004, European journal of haematology.

Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods

Øystein Bruserud, T. Hervig, Ø. Bruserud, 2010, Transfusion.

Therapeutic Targeting the Cell Division Cycle 25 (CDC25) Phosphatases in Human Acute Myeloid Leukemia — The Possibility to Target Several Kinases through Inhibition of the Various CDC25 Isoforms

Håkon Reikvam, Antonio Lavecchia, Øystein Bruserud, 2014, Molecules.

Connexin expression in human acute myeloid leukemia cells: Identification of patient subsets based on protein and global gene expression profiles

Ø. Bruserud, H. Reikvam, A. Ryningen, 2014, International journal of molecular medicine.

Characterization of Ribosomal P Autoantibodies in Relation to Cell Destruction and Autoimmune Disease

Ø. Bruserud, T. Bredholt, B. Gjertsen, 2004, Scandinavian journal of immunology.

CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles

T. H. Bø, I. Jonassen, Ø. Bruserud, 2005, Cytometry. Part B, Clinical cytometry.

Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses.

L. Hood, Ø. Bruserud, K. Kalland, 2002, Journal of hematotherapy & stem cell research.

The Immunological Dilemma: Cellular Innate and Adaptive Immune Response Versus Human Acute Myeloid Leukemia

Ø. Bruserud, E. Ersvær, A. Olsnes, 2007 .

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation

Håkon Reikvam, Bjørn Tore Gjertsen, Øystein Bruserud, 2014, Oncotarget.

Emerging therapeutic targets in human acute myeloid leukemia (part 2) – bromodomain inhibition should be considered as a possible strategy for various patient subsets

Ø. Bruserud, H. Reikvam, T. Hoang, 2015, Expert review of hematology.

Modified fatty acids and their possible therapeutic targets in malignant diseases

Ø. Bruserud, K. Tronstad, R. Berge, 2003, Expert opinion on therapeutic targets.

Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death.

Ø. Bruserud, J. Vandekerckhove, S. Døskeland, 2008, Blood.

The protein kinase C agonist PEP005 increases NF‐κB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells

Ø. Bruserud, J. Lord, B. Gjertsen, 2009, British journal of haematology.

Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells

Ø. Bruserud, H. Reikvam, K. Hatfield, 2014, Expert opinion on therapeutic targets.

Targeting Cellular Metabolism in Acute Myeloid Leukemia and the Role of Patient Heterogeneity

Ø. Bruserud, T. Tvedt, H. Reikvam, 2020, Cells.

AcuteMyeloid Leukemia with the t ( 8 ; 21 ) Translocation : Clinical Consequences and Biological Implications

Ø. Bruserud, H. Reikvam, R. Hovland, 2014 .

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications

Håkon Reikvam, Øystein Bruserud, Ø. Bruserud, 2011, Journal of biomedicine & biotechnology.

A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia

Ø. Bruserud, S. Døskeland, A. Brenner, 2019, Molecular Cancer Therapeutics.

Clonal Heterogeneity Reflected by PI3K-AKT-mTOR Signaling in Human Acute Myeloid Leukemia Cells and Its Association with Adverse Prognosis

Ø. Bruserud, T. Tvedt, H. Reikvam, 2018, Cancers.

Paper I WILD TYPE P53 IS EXPRESSED AND PHOSPHORYLATED IN LEUKEMIA CELLS WITH FLT3 Y591 AMPLIFICATION AND BCL-2 OVEREXPRESSION

G. Nolan, A. Børresen-Dale, Ø. Bruserud, 2006 .

Paper IV p53 protein biosignatures correlate with chemotherapy response and survival in acute leukemia

Ø. Bruserud, B. Gjertsen, W. V. Belle, 2006 .

Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2009, Critical reviews in oncogenesis.

The Capacity of Long-Term In Vitro Proliferation of Acute Myeloid Leukemia Cells Supported Only by Exogenous Cytokines Is Associated with a Patient Subset with Adverse Outcome

Ø. Bruserud, A. Brenner, F. Berven, 2019, Cancers.

Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling

Ø. Bruserud, K. Tronstad, Linn Hodneland, 2007, Expert opinion on therapeutic targets.

Connexin-based signaling in acute myelogenous leukemia (AML).

Ø. Bruserud, K. Tronstad, B. Foss, 2010, Biochimica et biophysica acta.

frequency in the repertoire of normal donors certain HLA-DR alleles and can be recognized by T cells found at low BCR/ABL leukemia oncogene fusion peptides selectively bind to

Ø. Bruserud, G. Pawelec, H. Kalbacher, 2011 .

Anticancer immunotherapy in combination with proapoptotic therapy.

Ø. Bruserud, B. Gjertsen, A. Olsnes, 2008, Current cancer drug targets.

The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells.

Ø. Bruserud, A. Brenner, H. Reikvam, 2015, Stem cell research.

Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells

Ø. Bruserud, B. Gjertsen, R. Hovland, 2007, Molecular Cancer.

New Strategies for the Treatment of Acute Myelogenous Leukemia: Differentiation Induction—Present Use and Future Possibilities

Ø. Bruserud, B. Gjertsen, 2000, Stem cells.

Antileukaemic effect of PI3K‐mTOR inhibitors in acute myeloid leukaemia‐gene expression profiles reveal CDC25B expression as determinate of pharmacological effect

Ø. Bruserud, J. Tamburini, H. Reikvam, 2014, British journal of haematology.

S100 Proteins in Acute Myeloid Leukemia12

Ø. Bruserud, A. Brenner, 2018, Neoplasia.

Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status – consequences and potentials for pharmacological intervention

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2012, British journal of haematology.

Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML

Ø. Bruserud, B. Gjertsen, K. Tronstad, 2006, Expert opinion on therapeutic targets.

Proteomic Profiling of Primary Human Acute Myeloid Leukemia Cells Does Not Reflect Their Constitutive Release of Soluble Mediators

Ø. Bruserud, A. Brenner, F. Berven, 2018, Proteomes.

Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults

Ø. Bruserud, T. Tvedt, H. Reikvam, 2019, Expert opinion on investigational drugs.

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia

Ø. Bruserud, B. Gjertsen, H. Mukherjee, 2016, Cell Death & Disease.

Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells

Ø. Bruserud, J. Lord, B. Gjertsen, 2014, Oncoscience.

T lymphocyte chemotactic chemokines in acute myelogenous leukemia (AML): local release by native human AML blasts and systemic levels of CXCL10 (IP-10), CCL5 (RANTES) and CCL17 (TARC)

Anita Ryningen, Øystein Bruserud, Ø. Bruserud, 2006, Cancer Immunology, Immunotherapy.

Effects of cytarabine and various anthracyclins on platelet activation: Characterization of in vitro effects and their possible clinical relevance in acute myelogenous leukemia

T. Hervig, Ø. Bruserud, E. Ulvestad, 2002, International journal of cancer.

Platelet functions and clinical effects in acute myelogenous leukemia

Ø. Bruserud, O. Bruserud, B. Foss, 2007, Thrombosis and Haemostasis.

Cryopreserving human peripheral blood progenitor cells with 5‐percent rather than 10‐percent DMSO results in less apoptosis and necrosis in CD34+ cells

Øystein Bruserud, Ø. Bruserud, Jenny Foss Abrahamsen, 2002, Transfusion.

Hematopoietic engraftment of dimethyl sulfoxide–depleted autologous peripheral blood progenitor cells

Ø. Bruserud, B. Østenstad, Ç. A. Akkök, 2009, Transfusion.

Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation

Ø. Bruserud, Ç. A. Akkök, I. Nesthus, 2008, Transfusion.

Better preservation of early hematopoietic progenitor cells when human peripheral blood progenitor cells are cryopreserved with 5 percent dimethylsulfoxide instead of 10 percent dimethylsulfoxide

Ø. Bruserud, L. Rusten, A. Bakken, 2004, Transfusion.

The viability of cryopreserved PBPC depends on the DMSO concentration and the concentration of nucleated cells in the graft.

Ø. Bruserud, K Liseth, J Foss Abrahamsen, 2005, Cytotherapy.

Cytokine Release Syndrome in the Immunotherapy of Hematological Malignancies: The Biology behind and Possible Clinical Consequences

Ø. Bruserud, T. Tvedt, Anh Khoi Vo, 2021, Journal of clinical medicine.

SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.

Ø. Bruserud, B. Gjertsen, S. Laín, 2014, Cell stem cell.

Co-transplantation of multipotent mesenchymal stromal cells in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.

Ø. Bruserud, K. Hatfield, L. Larun, 2016, Cytotherapy.

Biological treatment in acute myelogenous leukaemia: how should T-cell targeting immunotherapy be combined with intensive chemotherapy?

Ø. Bruserud, Øystein Wendelboe, 2001, Expert opinion on biological therapy.

Acute myelogenous leukemia blasts as accessory cells during T lymphocyte activation: possible implications for future therapeutic strategies

Ø. Bruserud, Øystein Bruserud, 1999, Leukemia.

The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?

Ø. Bruserud, E. Ersvær, A. Kittang, 2011, Expert review of hematology.

The Possible Diagnostic and Prognostic Use of Systemic Chemokine Profiles in Clinical Medicine—The Experience in Acute Myeloid Leukemia from Disease Development and Diagnosis via Conventional Chemotherapy to Allogeneic Stem Cell Transplantation

Ø. Bruserud, H. Reikvam, A. Kittang, 2013, Toxins.

Preconditioning Serum Levels of Endothelial Cell-Derived Molecules and the Risk of Posttransplant Complications in Patients Treated with Allogeneic Stem Cell Transplantation

Ø. Bruserud, T. Tvedt, H. Reikvam, 2014, Journal of transplantation.

Early gene expression of acute myeloid leukemia in response to chemotherapy

Ø. Bruserud, K. Kalland, B. Gjertsen, 2007, Expert review of anticancer therapy.

Proteomic Studies of Primary Acute Myeloid Leukemia Cells Derived from Patients Before and during Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid and Valproic Acid

Ø. Bruserud, H. Reikvam, F. Berven, 2021, Cancers.

Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress

Ø. Bruserud, A. Brenner, F. Berven, 2021, Hemato.

Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients

Ø. Bruserud, E. Ersvær, A. Ryningen, 2019, BMC Immunology.

NewStrategies in the Treatment of Acute Myelogenous Leukemia: Mobilization and Transplantation of Autologous Peripheral Blood Stem Cells in Adult Patients

Ø. Bruserud, B. Gjertsen, G. Tjønnfjord, 2001, Stem cells.

The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity

Ø. Bruserud, J. Lord, B. Gjertsen, 2010, Toxins.

Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells

Ø. Bruserud, B. Gjertsen, J. Skavland, 2010, BMC Immunology.

Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism

Ø. Bruserud, A. Brenner, H. Reikvam, 2018, International journal of molecular sciences.

Cytokines, Adhesion Molecules, and Matrix Metalloproteases as Predisposing, Diagnostic, and Prognostic Factors in Venous Thrombosis

Ø. Bruserud, H. Reikvam, K. A. Mosevoll, 2018, Front. Med..

Platelet-released supernatants enhance hematopoietic stem cell proliferation in vitro

T. Hervig, Ø. Bruserud, B. Foss, 2008, Platelets.

Effects of normal platelets on proliferation and constitutive cytokine secretion by human acute myelogenous leukaemia blasts.

T. Hervig, Ø. Bruserud, B. Foss, 1997, Platelets.

Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia

Ø. Bruserud, B. Gjertsen, R. Kopperud, 2019, Journal of Cancer Research and Clinical Oncology.

Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy

Ø. Bruserud, B. Gjertsen, K. Hatfield, 2019, Cells.

At least five antigenic epitopes on the streptokinase molecule are recognized by human CD4+ TCRαβ+ T cells

Ø. Bruserud, G. Pawelec, S. Elsayed, 1992 .

The Role of the CD8‐Positive Subset of T Cells in Proliferative Responses to Soluble Antigens

E. Thorsby, Ø. Bruserud, L. Sollid, 1986, Scandinavian journal of immunology.

Functional evaluation of proliferative T cell responses in patients with severe T lymphopenia: characterization of optimal culture conditions and standardized activation signals for a simple whole blood assay.

Ø. Bruserud, Ø. Wendelbo, 2003, Journal of hematotherapy & stem cell research.

CD4+TCRαβ+ T-cells developing after allogeneic bone marrow transplantation in patients with chronic myelogenous leukaemia. Dipyridamole inhibits functionally heterogeneous T-cell clones

Ø. Bruserud, G. Pawelec, Sarita Patel, 1991 .

The additive effect of certain drugs on the Cyclosporine A inhibition of human T‐cell proliferation

Ø. Bruserud, 1990, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation

Ø. Bruserud, T. Tvedt, H. Reikvam, 2021, Pharmaceuticals.

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2017, BMC Cancer.

Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors.

Ø. Bruserud, K. Kalland, G. Eide, 2007, International journal of oncology.

The Possible Importance of β3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia

Ø. Bruserud, A. Brenner, H. Reikvam, 2018, International journal of molecular sciences.

Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents

Ø. Bruserud, B. Gjertsen, Hanne K Fredly, 2013, Clinical Epigenetics.

Clonogenic acute myelogenous leukemia cells are heterogeneous with regard to regulation of differentiation and effect of epigenetic pharmacological targeting.

Ø. Bruserud, A. Ryningen, C. Stapnes, 2007, Leukemia research.

Therapeutic targeting of leukemic stem cells in acute myeloid leukemia – the biological background for possible strategies

Ø. Bruserud, H. Reikvam, M. Hernandez-Valladares, 2017, Expert opinion on drug discovery.

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia

Ø. Bruserud, B. Gjertsen, H. Mukherjee, 2016, Cell Death & Disease.

The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia.

Ø. Bruserud, F. Selheim, C. Hinrichs, 2015, Current pharmaceutical biotechnology.

The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status

Ø. Bruserud, H. Reikvam, R. Hovland, 2012, Leukemia.

High Constitutive Cytokine Release by Primary Human Acute Myeloid Leukemia Cells Is Associated with a Specific Intercellular Communication Phenotype

Ø. Bruserud, A. Brenner, H. Reikvam, 2019, Journal of clinical medicine.

Bone marrow abnormalities detected by magnetic resonance imaging as initial sign of hematologic malignancies

Ø. Bruserud, H. Reikvam, N. Vetti, 2018, Clinics and practice.

Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia--targeting of disease heterogeneity through direct and indirect antileukemic effects.

Ø. Bruserud, H. Reikvam, K. Hatfield, 2011, Leukemia research.

Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia

Ø. Bruserud, I. Nesthus, M. Sjo, 2004, Cancer Immunology, Immunotherapy.

The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation.

Ø. Bruserud, H. Reikvam, K. Hatfield, 2012, European cytokine network.

The chemokine network in acute myelogenous leukemia: molecular mechanisms involved in leukemogenesis and therapeutic implications.

Ø. Bruserud, H. Reikvam, A. Kittang, 2010, Current topics in microbiology and immunology.

In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation

Ø. Bruserud, G. Pawelec, I. Nesthus, 2004, Cancer Chemotherapy and Pharmacology.

In vitro culture of human acute lymphoblastic leukemia (ALL) cells in serum-free media; a comparison of native ALL blasts, ALL cell lines and virus-transformed B cell lines.

Ø. Bruserud, E. Ulvestad, A. Ryningen, 2003, Leukemia research.

Antiproliferative effects of a non-β-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures

Ø. Bruserud, K. Tronstad, R. Berge, 2002, Leukemia.

In vitro effects of insulin‐like growth factor‐1 (IGF‐1) on proliferation and constitutive cytokine secretion by acute myelogenous leukemia blasts

Ø. Bruserud, S. Frostad, 1999, European journal of haematology.

Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy‐ induced leucopenia

Ø. Bruserud, I. Aasen, P. Akselsen, 1996, European journal of haematology.

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia

Ø. Bruserud, B. Gjertsen, E. McCormack, 2016, Oncotarget.

Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells

Ø. Bruserud, H. Reikvam, F. Berven, 2019, Signal Transduction and Targeted Therapy.

The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation

Ø. Bruserud, H. Reikvam, K. Hatfield, 2015, Metabolomics.

Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels

Ø. Bruserud, K. Kalland, B. Gjertsen, 2008, Leukemia.

Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts.

Ø. Bruserud, B. Gjertsen, A. Ryningen, 2004, Haematologica.

Nutrition in Allogeneic Stem Cell Transplantion--Clinical Guidelines and Immunobiological Aspects.

Ø. Bruserud, T. Tvedt, H. Reikvam, 2015, Current Pharmaceutical Biotechnology.

Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex

Ø. Bruserud, J. Lord, B. Gjertsen, 2007, Hematology.

T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-γ that can be further increased by a novel protein kinase C agonist PEP005

Ø. Bruserud, J. Lord, B. Gjertsen, 2007, Cancer Immunology, Immunotherapy.

A pilot study of single nucleotide polymorphisms in the interleukin‐6 receptor and their effects on pre‐ and post‐transplant serum mediator level and outcome after allogeneic stem cell transplantation

Ø. Bruserud, T. Tvedt, R. Hovland, 2018, Clinical and experimental immunology.

Proteomic Comparison of Bone Marrow Derived Osteoblasts and Mesenchymal Stem Cells

Ø. Bruserud, A. Brenner, F. Berven, 2021, International journal of molecular sciences.

The Extracellular Bone Marrow Microenvironment—A Proteomic Comparison of Constitutive Protein Release by In Vitro Cultured Osteoblasts and Mesenchymal Stem Cells

Ø. Bruserud, A. Brenner, F. Berven, 2020, Cancers.

Functional Toll-Like Receptors (TLRs) Are Expressed by a Majority of Primary Human Acute Myeloid Leukemia Cells and Inducibility of the TLR Signaling Pathway Is Associated with a More Favorable Phenotype

Ø. Bruserud, A. Brenner, 2019, Cancers.

Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison

Ø. Bruserud, B. Gjertsen, A. Brenner, 2018, Expert opinion on therapeutic targets.

Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism

Ø. Bruserud, T. Tvedt, A. Brenner, 2017, Expert opinion on therapeutic targets.

Targeting of cell metabolism in human acute myeloid leukemia – more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?

Ø. Bruserud, K. Hatfield, Michelle V. Hauge, 2016, European journal of haematology.

STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia

Ø. Bruserud, H. Reikvam, K. Hatfield, 2015, Expert review of hematology.

Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients

Ø. Bruserud, K. Kalland, H. Reikvam, 2013, Cell proliferation.

Effects of interferon gamma on native human acute myelogenous leukaemia cells

Ø. Bruserud, B. Gjertsen, J. Skavland, 2006, Cancer Immunology, Immunotherapy.

The angioregulatory phenotype of native human acute myelogenous leukemia cells: influence of karyotype, Flt3 abnormalities and differentiation status

Ø. Bruserud, R. Hovland, N. Glenjen, 2003, European journal of haematology.

Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts.

Ø. Bruserud, B. Gjertsen, Tien‐sheng Huang, 2002, Haematologica.

Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis

Ø. Bruserud, M. Lanotte, S. Døskeland, 2013, Cell Death & Disease.

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies.

Ø. Bruserud, B. Gjertsen, A. Olsnes, 2005, Current cancer drug targets.

The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia

Ø. Bruserud, B. Gjertsen, E. Ersvær, 2013, Clinical Epigenetics.

Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia

Sigrun M. Hjelle, P. Lønning, S. Knappskog, 2012, Oncogene.

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2018, Biomarker Research.

IL2‐ and IL4‐dependent proliferation of T‐cell clones derived early after allogeneic bone marrow transplantation: Studies of patients with chronic myelogenous leukaemia

Ø. Bruserud, G. Pawelec, G. Ehninger, 1992, European journal of haematology.

Performance of super‐SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines

Ø. Bruserud, S. Døskeland, B. Gjertsen, 2014, Proteomics.

High Dose Ara‐C Combined with Autologous Peripheral Blood Stem Cell Transplantation in the Treatment of Acute Myelogenous Leukemia: The Question is Still Not Answered

Ø. Bruserud, P. Ernst, 2000, Stem cells.

Effects Of Benzene on Human Hematopoiesis

Ø. Bruserud, B. Moen, T. Riise, 2008 .

Serum levels of thrombopoietin and stem cell factor in acute leukemia patients with chemotherapy-induced cytopenia and complicating infections.

Ø. Bruserud, B. Foss, J. Bergheim, 1999, Platelets.

Serum thrombopoietin levels in acute leukemia patients with chemotherapy-induced cytopenia – inverse correlation between serum levels and platelet counts

Ø. Bruserud, B. Foss, 1998, Leukemia.

The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers--a comparative study of serum versus plasma samples.

Ø. Bruserud, T. Tvedt, A. Brenner, 2015, Journal of immunological methods.

Serum levels of soluble ICAM-1 in acute leukemia patients with chemotherapy-induced neutropenia

Ø. Bruserud, 1997, Leukemia.

Patients with Bacterial Sepsis Are Heterogeneous with Regard to Their Systemic Lipidomic Profiles

Ø. Bruserud, Øyvind Bruserud, K. A. Mosevoll, 2022, Metabolites.

Precision medicine for TP53-mutated acute myeloid leukemia

Ø. Bruserud, T. Tvedt, H. Reikvam, 2019, Expert Review of Precision Medicine and Drug Development.

Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia

S. Knappskog, Ø. Bruserud, B. Gjertsen, 2012, Leukemia.

The Regulation of Neutrophil Migration in Patients with Sepsis: The Complexity of the Molecular Mechanisms and Their Modulation in Sepsis and the Heterogeneity of Sepsis Patients

Ø. Bruserud, Øyvind Bruserud, K. A. Mosevoll, 2023, Cells.

Serum concentrations of E‐selectin, P‐selectin, ICAM‐1 and interleukin 6 in acute leukaemia patients with chemotherapy‐induced leucopenia and bacterial infections

Ø. Bruserud, J. Bergheim, I. Nesthus, 1995, British journal of haematology.

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia

Ø. Bruserud, B. Gjertsen, S. Laín, 2014, Molecular Cancer.

Giardia-specific cellular immune responses in post-giardiasis chronic fatigue syndrome

Ø. Bruserud, S. Svärd, N. Langeland, 2017, BMC Immunology.

Flt 3 Y 591 duplication and Bcl-2 overexpression are detected in acute myeloid leukemia cells with high levels of phosphorylated wild-type p 53

G. Nolan, A. Børresen-Dale, Ø. Bruserud, 2006 .

Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows.

Ø. Bruserud, F. Berven, Marc Vaudel, 2016, Journal of proteomics.

Interleukin-7 (IL-7) in patients receiving intensive chemotherapy for acute myelogenous leukemia: studies of systemic IL-7 Levels and IL-7 responsiveness of circulating T lymphocytes.

Ø. Bruserud, N. Glenjen, Ø. Wendelbo, 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

The Constitutive Extracellular Protein Release by Acute Myeloid Leukemia Cells—A Proteomic Study of Patient Heterogeneity and Its Modulation by Mesenchymal Stromal Cells

Ø. Bruserud, T. Tvedt, A. Brenner, 2021, Cancers.

Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells

Ø. Bruserud, A. Brenner, F. Berven, 2021, Diseases.

Systemic Metabolomic Profiles in Adult Patients with Bacterial Sepsis: Characterization of Patient Heterogeneity at the Time of Diagnosis

Ø. Bruserud, Øyvind Bruserud, K. A. Mosevoll, 2023, Biomolecules.

Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables

Kjell Arild Høgda, Werner Van Belle, Bjørn Tore Gjertsen, 2006, BMC Bioinformatics.

[A man in his 80s with muscle stiffness and skin bleeding].

Ø. Bruserud, T. Tvedt, P. Holme, 2014, Tidsskrift for Den Norske Laegeforening.

Targeted therapy in acute myeloid leukaemia: current status and future directions.

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2009, Expert opinion on investigational drugs.

Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy

Ø. Bruserud, T. Hausken, A. Ryningen, 2006, Platelets.

Pretransplant Levels of CRP and Interleukin-6 Family Cytokines; Effects on Outcome after Allogeneic Stem Cell Transplantation

Ø. Bruserud, T. Tvedt, H. Reikvam, 2016, International journal of molecular sciences.

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia – identification of responders by gene expression profiling of pretreatment leukemic cells

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2017, BMC Cancer.

Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.

Siv Lise Bedringaas, Ø. Bruserud, B. Gjertsen, 2018, Journal of proteomics.

Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients

Ø. Bruserud, F. Berven, Marc Vaudel, 2016, Biological Procedures Online.

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biological effects, and impact on quality of life

Ø. Bruserud, O. Linder, H. Pahl, 2006 .

Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells

Ø. Bruserud, 1998, Cancer Immunology, Immunotherapy.

Granulocyte colony-stimulating factor alters the systemic metabolomic profile in healthy donors

Ø. Bruserud, G. Melve, K. Hatfield, 2016, Metabolomics.

A prospective observational study on effects of fever on red cell transfusion outcome

T. Hervig, Ø. Bruserud, H. Reikvam, 2017, Vox sanguinis.

Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia.

Ø. Bruserud, B. Gjertsen, E. McCormack, 2013, Blood.

NK Cells with KIR2DS2 Immunogenotype Have a Functional Activation Advantage To Efficiently Kill Glioblastoma and Prolong Animal Survival

Ø. Bruserud, J. Zimmer, L. Leiss, 2014, The Journal of Immunology.

The association between cytokines and psychomotor speed in a spectrum of psychotic disorders: A longitudinal study

Ø. Bruserud, M. Rettenbacher, S. Reitan, 2021, Brain, behavior, & immunity - health.

Clinical proteomics of myeloid leukemia

Sigrun M. Hjelle, Ø. Bruserud, B. Gjertsen, 2010, Genome Medicine.

[Acute promyelocytic leukaemia].

Ø. Bruserud, H. Reikvam, R. Hovland, 2014, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2018, Biomarker Research.

Immunological heterogeneity of healthy peripheral blood stem cell donors – preharvesting donor characteristics, additional heterogeneity induced by granulocyte colony-stimulating factor and possible importance for outcome after allotransplantation

Ø. Bruserud, T. Tvedt, T. Gedde-Dahl, 2018, Expert Review of Hematology.

Ø. Bruserud, E. Ersvær, A. Ryningen, 2019, BMC Immunology.

Minor diurnal and activity-induced variations in daytime peripheral blood platelet counts do not have any major impact on platelet yield by platelet apheresis.

T. Hervig, Ø. Bruserud, E. Ersvaer, 2010, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Inflammatory Mediator Profiles Differ in Sepsis Patients With and Without Bacteremia

Ø. Bruserud, J. Assmus, H. Reikvam, 2018, Front. Immunol..

Interleukin 4 (IL4), IL10 and IL13 Inhibit in vitro Cytokine Secretion by Acute Myelogenous Leukemia Blasts in the Presence of Exogenous Hematopoietic Growth Factors.

Ø. Bruserud, 1998, Hematology.

Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: Will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions?

Ø. Bruserud, B. Gjertsen, H. Reikvam, 2012, Current cancer drug targets.

Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome

Ø. Bruserud, G. Mufti, T. Seidl, 2015, Oncoimmunology.

Review: genetic models of acute myeloid leukaemia

Ø. Bruserud, B. Gjertsen, E. McCormack, 2008, Oncogene.

Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine

H. Aarstad, Ø. Bruserud, T. Bredholt, 2013, BMC Pharmacology and Toxicology.